Physician profile
Pierre Hindy
NPI 1164605903
$8,152.34
in general payments reported to CMS, 2019-2025
31 companies · $1,321 in 2025
The $1,321 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $577 · 2021: $1,376 · 2022: $1,071 · 2023: $1,537 · 2024: $1,333 · 2025: $1,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,190.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,943.57 | 2019-2025 | |
| Pfizer INC. | $813.71 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $534.63 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $503.27 | 2019-2024 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $462.90 | 2019-2025 | |
| Celgene Corporation | $444.46 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $321.81 | 2021-2025 | Omvoh, Zepbound, Mounjaro |
| Janssen Biotech, INC. | $313.20 | 2020-2025 | Tremfya, Stelara |
| Aimmune Therapeutics, INC. | $284.11 | 2024-2025 | Zenpep, Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $228.14 | 2019-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $155.76 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $139.61 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $139.39 | 2021-2023 | Clenpiq |
| Redhill Biopharma INC. | $114.84 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $89.73 | 2019-2024 | Dificid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $85.25 | 2021-2023 | |
| Madrigal Pharmaceuticals | $78.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Vivus LLC | $76.13 | 2020-2024 | Pancreaze |
| Currax Pharmaceuticals LLC | $66.33 | 2022-2024 | Contrave |
| Romark Laboratories, Lc | $57.06 | 2020 | |
| Braintree Laboratories, INC. | $51.66 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $45.03 | 2021-2022 | |
| Celltrion USA INC. | $34.16 | 2025 | Vegzelma |
| Eisai INC. | $30.43 | 2024 | |
| Genzyme Corporation | $30.37 | 2024 | |
| Qol Medical, LLC | $24.63 | 2023 | Sucraid |
| Allergan, INC. | $23.08 | 2019 | |
| Concordia Pharmaceuticals INC. | $19.70 | 2019 | |
| Intra-Sana Laboratories | $15.23 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $12.92 | 2024 | Sureclip |
| Intercept Pharmaceuticals, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pierre Hindy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.